NCT02191163已完成2 期
A 17 Week, Randomised, Double-blind, Placebo Controlled Cross-over Trial to Evaluate the Efficacy of Antistax® Film Coated Tablets (Extr. Vitis Vinifera Siccum), 360 mg/Day p.o. in Improving Microcirculation of the Skin in the Leg of Male and Female Patients Suffering From Chronic Venous Insufficiency
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 71
- 主要终点
- Changes from baseline in the resting flux
研究概览
简要总结
Study to determine the efficacy and safety of Antistax® film coated tablets in improving microcirculation of the skin in the leg of patients with chronic venous insufficiency (CVI)
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female
- •>= 18 years of age
- •CVI I or CVI II (without expanded trophic disturbances)
- •Willing and able to give written informed consent in accordance to Good Clinical Practice and local legislation prior to participation in the study
排除标准
- •Concomitant disease(s) exclusion criteria:
- •Decompensated cardiac insufficiency
- •Edema not due to venous disease of the legs (e.g. latent cardiac insufficiency, renal insufficiency, lymph edema, etc)
- •Peripheral arterial disease (ankle/arm pressure index < 0.9)
- •Current acute phlebitis or thrombosis
- •Renal insufficiency (Serum creatinine > 1.5 mg/dl)
- •Liver disease (SGPT (ALAT) > 3x upper limit of normal)
- •Other diseases: insulin-dependent diabetes mellitus, neuropathies, hyper- or hypocalcaemia, malignancies
- •Anamnestic indications of diabetic microangiopathy or polyneuropathy
- •Drug and/or alcohol abuse
- •Pregnant or nursing women or inadequate birth control methods (this applies to females of childbearing potential only)
- •Severe climacteric complaints or changes in, or initiation with post-menopausal hormone replacement therapy within the last 3 months
- •Immobility
- •Avalvulie
- •Klippel-Trénaunay-Weber-Syndrome (Naevus varicosis osteohypertrophicus, Haemangiectasia hypertrophicans)
- •State after pulmonary embolism
- •Recognized hypersensitivity to the trial drug ingredients
- •Current florid venous ulcus
- •Clinical indication for a necessary, specific phlebologic acute treatment, e.g. compressive treatment, phlebectomy, etc.
- •Previous treatment(s) exclusion criteria:
- •Treatment with venous drugs within the last 4 weeks
- •Changes in, or initiation with, treatment with theophylline, diuretics, cardiac glycosides, ACE inhibitors or calcium antagonists within the last 8 days
- •Concomitant treatment/non-drug therapy exclusion criteria:
- •Other venous drugs apart from the trial medication
- •Compression bandages
- •Venous surgery of the leg used for the fluxmetry
- •Extensive use (i.e. on more than a total of 6 days during the entire trial) of laxatives which affect fluid or electrolyte balance
- •Major surgery requiring full anesthesia
- •Other exclusion criteria:
- •Previously studied under this protocol
- •Participation in another clinical trial within the previous 90 days or during the present study
- •Patients considered as mentally ill as well as unable to work or with limited working ability, or unable (or only partially able) to follow the spoken or written explanations concerning the trial
- •Patients in a bad general health state according to the investigator's judgment
研究组 & 干预措施
Antistax®
Experimental
1 x 360 mg for 42 days
干预措施: Antistax® (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Changes from baseline in the resting flux
时间窗: Baseline, after 6 weeks of treatment
measured in the frequency range 10-37 kHz on the skin of the inside lower leg using the Laser Doppler Fluxmetry
次要结局
- Changes from baseline in the resting flux(Baseline, after 3 weeks of treatment)
- Changes in the resting flux(Baseline, after 3 and 6 weeks of treatment)
- Changes in the combined resting fluxes (<37 kHz)(Baseline, after 3 and 6 weeks of treatment)
- Changes in the transcutaneous oximetry (TcPO2)(Baseline, after 3 and 6 weeks of treatment)
- Change from baseline in the calf circumference of the most affected leg(Baseline, after 3 and 6 weeks of treatment)
- Change from baseline in the ankle circumference of the most affected leg(Baseline, after 3 and 6 weeks of treatment)
- Change from baseline in the subjective symptoms of CVI measured by Visual Analogue Scales (VAS)(Baseline, after 3 and 6 weeks of treatment)
- Global efficacy assessment by patient on a 4-point verbal rating scale (VRS)(after 6 weeks of treatment)
- Global efficacy assessment by investigator on a 4-point VRS(after 6 weeks of treatment)
- Number of patients with adverse events(up to 16 weeks)
- Number of patients with clinically relevant changes in laboratory values(Baseline, up to 16 weeks)
- Number of patients with clinically significant changes in vital signs(Baseline, up to 16 weeks)
- Global tolerability assessment by investigator on a 4-point VRS(after 6 weeks of treatment)
- Global tolerability assessment by patient on a 4-point VRS(after 6 weeks of treatment)
研究者
相似试验
已完成
3 期
Efficacy and Tolerability of Antistax® in Male and Female Patients Suffering From Chronic Venous InsufficiencyVenous InsufficiencyNCT02191254Boehringer Ingelheim245
已完成
3 期
Assess the Efficacy and Tolerability of Antistax Film-coated Tablets in Patients With Chronic Venous InsufficiencyVenous InsufficiencyNCT00855179Boehringer Ingelheim250
已完成
4 期
Tolerability of Antistax® in Patients Suffering From Chronic Venous Insufficiency (CVI)Venous InsufficiencyNCT02184234Boehringer Ingelheim65
已完成
2 期
Antistax® in Patients With Chronic Venous InsufficiencyVenous InsufficiencyNCT02191280Boehringer Ingelheim260
已完成
3 期
Efficacy and Tolerability CVI (A 12-week, Double-blind, Randomised, Placebo-controlled, Multicentre Trial (CVI)Venous InsufficiencyNCT00292435Boehringer Ingelheim202